Renal Cancer - Results from #1560

Tumor-Educated Platelets as a Promising Biomarker for Blood-Based Detection of Renal Cell Carcinoma. March 28, 2022

Survival after minimally invasive vs. open radical nephrectomy for stage I and II renal cell carcinoma. March 25, 2022

Survival Prognosis, Tumor Immune Landscape, and Immune Responses of PPP1R18 in Kidney Renal Clear Cell Carcinoma and Its Potentially Double Mechanisms. March 25, 2022

Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents. March 24, 2022

Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients. March 24, 2022

The relationship between blood pressure and risk of renal cell carcinoma. March 23, 2022

New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. March 23, 2022

First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. March 22, 2022

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. March 22, 2022

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. March 21, 2022

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. March 21, 2022

Can kidney parenchyma metabolites serve as prognostic biomarkers for long-term kidney function after nephrectomy for renal cell carcinoma? A preliminary study. March 18, 2022

Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. March 18, 2022

A Web-Based Prediction Model for Cancer-Specific Survival of Middle-Aged Patients With Non-metastatic Renal Cell Carcinoma: A Population-Based Study. March 17, 2022

Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. March 17, 2022

Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. March 16, 2022

Recent pharmacological approaches for the treatment of renal cell carcinoma. March 16, 2022

Safety and Oncologic Outcomes of Percutaneous Cryoablation of Renal Cell Carcinoma Recurrences in the Ipsilateral Kidney Following Partial Nephrectomy. March 15, 2022

Contrast-enhanced CT immediately following percutaneous microwave ablation of cT1a renal cell carcinoma: Optimizing cancer outcomes. March 15, 2022

The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma. March 14, 2022

Page 79 of 456